Predicted solution structure of zymogen human coagulation FVII

Perera, Lalith; Darden, Thomas A.; Pedersen, Lee G.

doi:10.1002/jcc.1155

Cited by 15 publications

(17 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It comprises the g-carboxyglutamic acid (Gla) domain, epidermal growth factor (EGF)-like 1, 2 domain, and the catalytic domain [22]. The distribution of mutations is heterogeneous; however, the majority of the mutations are located within the catalytic domain [1,23].…”

Section: Discussionmentioning

confidence: 99%

Combined congenital dysfibrinogenemia and factor VII deficiency from mutations in the FGB and F7 genes

Woo

Park²,

Lee³

et al. 2012

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Dysfibrinogenemia and factor VII (FVII) deficiency are rare congenital coagulopathies. In this report, the authors describe a man with both defects confirmed by molecular genetic tests. The patient was a 51-year-old man referred for prolonged prothrombin time (PT) that had been accidentally detected on preoperative screening. He had no history of bleeding tendency even on occasions of surgery. Routine coagulation studies revealed prolonged PT (1.53 INR) and thrombin time (42.2 s), and decreased fibrinogen level (57 mg/dl) and FVII activity (44%). Direct sequencing analyses were performed on FGA, FGB, and FGG genes to confirm dysfibrinogenemia and on the F7 gene to confirm FVII deficiency. As a result, the patient was shown to be heterozygous for a point mutation in exon 8 of the FGB gene (c.1475A > G, p.*492Trpext*12; Fibrinogen Magdeburg II) and for a missense mutation in exon 6 of the F7 gene (c.466G > A, p.Gly156Ser). To our knowledge, this is the first report on a case of combined dysfibrinogenemia and FVII deficiency confirmed by molecular genetic tests.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined congenital dysfibrinogenemia and factor VII deficiency from mutations in the FGB and F7 genes

Woo

Park²,

Lee³

et al. 2012

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…A composite structural model of the zymogenic form of FVII (residues 1 to 406) was built using existing X-ray crystallographic data (27,28) as well as a computational model of the full-length protein (29). Atomicresolution information is available for HAdv5 hexon (11,12).…”

Section: Methodsmentioning

confidence: 99%

Coagulation Factor Binding Orientation and Dimerization May Influence Infectivity of Adenovirus-Coagulation Factor Complexes

Irons

Flatt

Doronin

et al. 2013

J Virol

View full text Add to dashboard Cite

d Adenoviruses (Ads) are promising vectors for therapeutic interventions in humans. When injected into the bloodstream, Ad vectors can bind several vitamin K-dependent blood coagulation factors, which contributes to virus sequestration in the liver by facilitating transduction of hepatocytes. Although both coagulation factors FVII and FX bind the hexon protein of human Ad serotype 5 (HAdv5) with a very high affinity, only FX appears to play a role in mediating Ad-hepatocyte transduction in vivo. To understand the discrepancy between efficacy of FVII binding to hexon and its apparently poor capacity for supporting virus cell entry, we analyzed the HAdv5-FVII complex by using high-resolution cryo-electron microscopy (cryo-EM) followed by molecular dynamic flexible fitting (MDFF) simulations. The results indicate that although hexon amino acids T423, E424, and T425, identified earlier as critical for FX binding, are also involved in mediating binding of FVII, the FVII GLA domain sits within the surface-exposed hexon trimer depression in a different orientation from that found for FX. Furthermore, we found that when bound to hexon, two proximal FVII molecules interact via their serine protease (SP) domains and bury potential heparan sulfate proteoglycan (HSPG) receptor binding residues within the dimer interface. In contrast, earlier cryo-EM studies of the Ad-FX interaction showed no evidence of dimer formation. Dimerization of FVII bound to Ad may be a contributing mechanistic factor for the differential infectivity of Ad-FX and Ad-FVII complexes, despite high-affinity binding of both these coagulation factors to the virus. V iral vectors based on adenoviruses (Ads) specific to human and animal species have been adapted widely for gene transfer applications both in vitro and in vivo. Extensive in vitro analyses have revealed a model of Ad cell infection whereby the initial virus attachment to a plasma membrane-localized receptor via the fiber protein is followed by virus penton interaction with integrins that mediate virion internalization into the cell (1, 2). To date, a number of cellular proteins that serve as functional high-affinity virus attachment receptors have been identified. For the most common vectors, based on species C human adenovirus serotype 5 (HAdv5), as well as for HAdv of species A, D, E, and F, it was found that a tight junction protein designated coxsackie and adenovirus receptor (CAR) can serve as a high-affinity attachment receptor (3-5). The species B Ads may utilize CD46 and/or DSG2 proteins to gain entry into host cells (6-8), while several species D Ads may utilize CD46, sialic acid, or GD1a glycan to enter the cell (9, 10). It was also shown that HAdv can bind a variety of integrin classes that interact with a penton RGD amino acid motif to trigger internalization of cell-bound virus particles into the cell (2).Although this canonical pathway of HAdv cell entry operates efficiently in vitro and explains the topology and functional interdependence between viral capsid proteins (11, 12), ...

show abstract

“…The molecular cause of these enhancements has been of considerable interest. As we earlier participated in studies of the dynamics of the light chain of FVIIa [4], the zymogen FVII [5], and the complex sTF–FVIIa [6], we here employ current theoretical methodology [7,8] to assess the dynamic differences in sTF–FVIIa and FVIIa in a consistent manner using molecular dynamics. The goal is to compare the equilibrated solution structure of the complexed and free FVIIa and thereby find differences that might provide clues as to the enhancement of sTF.…”

mentioning

confidence: 99%

“…The AMBER 8/PMEMD8 molecular dynamics program was employed [8]. Overall, the protocol was similar to that employed in a previous study [5]. Two simulations were performed: (i) the solvated sTF–FVIIa complex; and (ii) FVIIa f .…”

mentioning

confidence: 99%